MiR-21-3p is a positive regulator of L1CAM in several human carcinomas

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 455-466

  Doberstein, Kai ^a   Bretz, Niko P ^a   Schirmer, Uwe ^a   Fiegl, Heidi ^b   Blaheta, Roman ^b   Breunig, Christian ^a   Müller Holzner, Elisabeth ^c   Reimer, Dan ^c   Zeimet, Alain G ^c   Altevogt, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Endometrial carcinoma; Kidney carcinoma; MiR 21 3; Ovarian carcinoma

Indexed keywords

CELL ADHESION MOLECULE; L1 CELL ADHESION MOLECULE; MESSENGER RNA; MICRORNA; MICRORNA 21 3P; MICRORNA 21 5P; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MIRN21 MICRORNA, HUMAN; NERVE CELL ADHESION MOLECULE L1; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CARCINOMA; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; L1CAM GENE; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; RENAL CELL CARCINOMA CELL LINE; TRANSCRIPTION INITIATION; BIOSYNTHESIS; CARCINOMA; ENDOMETRIUM TUMOR; GENETICS; KIDNEY TUMOR; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

CARCINOMA; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908012732     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.020     Document Type: Article

References (50)

1. Gavert N., Ben-Shmuel A., Raveh S., Ben-Ze'ev A. L1-CAM in cancerous tissues. Expert Opin. Biol. Ther 2008, 8:1749-1757.
2. Schafer M.K., Altevogt P. L1CAM malfunction in the nervous system and human carcinomas. Cell. Mol. Life Sci 2010, 67:2425-2437.
3. Haspel J., Grumet M. The L1CAM extracellular region: a multi-domain protein with modular and cooperative binding modes. Front. Biosci 2003, 8:s1210-s1225.
4. Maness P.F., Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat. Neurosci 2007, 10:19-26.
5. Ben Q.W., Wang J.C., Liu J., Zhu Y., Yuan F., Yao W.Y., et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol 2010, 17:2213-2221.
6. Bergmann F., Wandschneider F., Sipos B., Moldenhauer G., Schniewind B., Welsch T., et al. Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol. Rep 2010, 24:909-915.
7. Bondong S., Kiefel H., Hielscher T., Zeimet A.G., Zeillinger R., Pils D., et al. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation. Ann. Oncol 2012, 23:1795-1802.
8. Boo Y.J., Park J.M., Kim J., Chae Y.S., Min B.W., Um J.W., et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann. Surg. Oncol 2007, 14:1703-1711.
9. Fogel M., Gutwein P., Mechtersheimer S., Riedle S., Stoeck A., Smirnov A., et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003, 362:869-875.
10. Wang Y.Y., Li L., Zhao Z.S., Wang Y.X., Ye Z.Y., Tao H.Q. L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients. J. Exp. Clin. Cancer Res 2013, 32:66.
11. Zeimet A.G., Reimer D., Huszar M., Winterhoff B., Puistola U., Azim S.A., et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J. Natl Cancer Inst 2013, 105:1142-1150.
12. Huszar M., Pfeifer M., Schirmer U., Kiefel H., Konecny G.E., Ben-Arie A., et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J. Pathol 2010, 220:551-561.
13. Kiefel H., Bondong S., Pfeifer M., Schirmer U., Erbe-Hoffmann N., Schafer H., et al. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kappaB activation. Carcinogenesis 2012, 33:1919-1929.
14. Sebens Muerkoster S., Werbing V., Sipos B., Debus M.A., Witt M., Grossmann M., et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007, 26:2759-2768.
15. Stoeck A., Gast D., Sanderson M.P., Issa Y., Gutwein P., Altevogt P. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol 2007, 104:461-469.
16. Gavert N., Ben-Shmuel A., Lemmon V., Brabletz T., Ben-Ze'ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J. Cell Sci 2010, 123:2135-2143.
17. Kiefel H., Pfeifer M., Bondong S., Hazin J., Altevogt P. Linking L1CAM-mediated signaling to NF-kappaB activation. Trends Mol. Med 2011, 17:178-187.
18. Kiefel H., Bondong S., Hazin J., Ridinger J., Schirmer U., Riedle S., et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh. Migr 2012, 6:374-384.
19. Kallunki P., Edelman G.M., Jones F.S. Tissue-specific expression of the L1 cell adhesion molecule is modulated by the neural restrictive silencer element. J. Cell Biol 1997, 138:1343-1354.
20. Kreisler A., Strissel P.L., Strick R., Neumann S.B., Schumacher U., Becker C.M. Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene 2010, 29:5828-5838.
21. Geismann C., Arlt A., Bauer I., Pfeifer M., Schirmer U., Altevogt P., et al. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. Int. J. Oncol 2011, 38:257-266.
22. Pfeifer M., Schirmer U., Geismann C., Schafer H., Sebens S., Altevogt P. L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol. Biol 2010, 11:64.
23. Gavert N., Conacci-Sorrell M., Gast D., Schneider A., Altevogt P., Brabletz T., et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol 2005, 168:633-642.
24. Doberstein K., Wieland A., Lee S.B., Blaheta R.A., Wedel S., Moch H., et al. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis 2011, 32:262-270.
25. Kato K., Maesawa C., Itabashi T., Fujisawa K., Otsuka K., Kanno S., et al. DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer. Int. J. Oncol 2009, 35:467-476.
26. Kuwajima A., Iwashita J., Murata J., Abe T. The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res 2007, 27:4163-4169.
27. Schirmer U., Fiegl H., Pfeifer M., Zeimet A.G., Muller-Holzner E., Bode P.K., et al. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens. BMC Cancer 2013, 13:156.
28. Chen C.Z. MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med 2005, 353:1768-1771.
29. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet 2009, 10:704-714.
30. Iorio M.V., Croce C.M. microRNA involvement in human cancer. Carcinogenesis 2012, 33:1126-1133.
31. Schirmer U., Doberstein K., Rupp A.K., Bretz N.P., Wuttig D., Kiefel H., et al. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget 2014, 5:462-472.
32. Lo T.F., Tsai W.C., Chen S.T. MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth. PLoS ONE 2013, 8:e75628.
33. Ryan M.J., Johnson G., Kirk J., Fuerstenberg S.M., Zager R.A., Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994, 45:48-57.
34. Gast D., Riedle S., Issa Y., Pfeifer M., Beckhove P., Sanderson M.P., et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008, 27:1281-1289.
35. Riedle S., Kiefel H., Gast D., Bondong S., Wolterink S., Gutwein P., et al. Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity. Biochem. J. 2009, 420:391-402.
36. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425:307-311.
37. Mechtersheimer S., Gutwein P., Agmon L.N., Stoeck A., Oleszewski M., Riedle S., et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J. Cell Biol 2001, 155:661-674.
38. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33:e179.
39. Doberstein K., Steinmeyer N., Hartmetz A.K., Eberhardt W., Mittelbronn M., Harter P.N., et al. MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 2013, 15:218-230.
40. Reimer D., Hubalek M., Kiefel H., Riedle S., Skvortsov S., Erdel M., et al. Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene 2011, 30:4038-4049.
41. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
42. Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73. Cancer Genome Atlas Research Network.
43. Liang Y.J., Wang Q.Y., Zhou C.X., Yin Q.Q., He M., Yu X.T., et al. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 2013, 34:713-722.
44. Visvanathan J., Lee S., Lee B., Lee J.W., Lee S.K. The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development. Genes Dev 2007, 21:744-749.
45. Tan G.S., Chiu C.H., Garchow B.G., Metzler D., Diamond S.L., Kiriakidou M. Small molecule inhibition of RISC loading. ACS Chem. Biol 2012, 7:403-410.
46. miRBase http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000077.
47. Winter J., Diederichs S. Argonaute-3 activates the let-7a passenger strand microRNA. RNA Biol 2013, 10:1631-1643.
48. Kumarswamy R., Volkmann I., Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011, 8:706-713.
49. Aure M.R., Leivonen S.K., Fleischer T., Zhu Q., Overgaard J., Alsner J., et al. Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol 2013, 14:R126.
50. Ganci F., Sacconi A., Bossel Ben-Moshe N., Manciocco V., Sperduti I., Strigari L., et al. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann. Oncol 2013, 24:3082-3088.